SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
August 09, 2022 07:30 ET
|
SIGA Technologies Inc.
- IV TPOXX is an Important Option for Those Unable to Swallow – - Option to Fund Post-Marketing Field Study for IV TPOXX also Exercised – NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SIGA...
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
August 04, 2022 16:05 ET
|
SIGA Technologies Inc.
- Approximately $9 Million of Product Sales in the Second Quarter, including First Oral TPOXX® Sale to the U.S. Department of Defense and Approximately $5 Million of International Sales – - Received...
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
July 28, 2022 16:15 ET
|
SIGA Technologies Inc.
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and...
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
July 15, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a...
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
July 12, 2022 16:15 ET
|
SIGA Technologies Inc.
- Approximately $26 Million of Orders Received from Canada underExisting Procurement Contracts –- Approximately $2 Million of Orders Received from Two New Jurisdictions - NEW YORK, July 12,...
SIGA Technologies Receives Approval from UK for Tecovirimat
July 08, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
June 23, 2022 08:00 ET
|
SIGA Technologies Inc.
NEW YORK, June 23, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced...
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
June 22, 2022 10:13 ET
|
SIGA Technologies Inc.
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that its...
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
May 19, 2022 07:30 ET
|
SIGA Technologies Inc.
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
May 12, 2022 16:05 ET
|
SIGA Technologies Inc.
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the...